Form 4: Silence Therapeutics Director, Iain Ross, Acquires 90,000 Share Options

Director Iain Ross acquired 90,000 share options in Silence Therapeutics plc on January 2, 2025.

Summary

• On January 2, 2025, Iain Ross, a director of Silence Therapeutics plc, acquired 90,000 share options.
• The exercise price of these options is $2.40.
• The options vest in equal monthly installments over a three-year period, starting one month after January 2, 2025, contingent upon continuous service.
• The options expire on January 2, 2035.
• Following the transaction, Ross directly owns 90,000 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of share options to a director is generally viewed as a positive sign, indicating confidence in the company's future prospects and aligning management's interests with those of shareholders.

Positives

• The acquisition of share options by a director signals confidence in the company's future performance.

Future Outlook

The vesting schedule indicates a long-term commitment from the director, aligning his interests with the company's performance over the next three years.

Industry Context

Share option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with shareholder value creation.

Comparison to Industry Standards

• Share option grants to directors are a standard practice across the biotechnology industry.
• The vesting schedule of three years is typical for such grants, aligning with industry norms for incentivizing long-term performance.
• Comparable companies like Alnylam Pharmaceuticals and Arrowhead Pharmaceuticals also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the option grant positively, as it aligns the director's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates